|
PMN
|
I can't believe how bad their video is, why post garbage that's only...
|
|
PMN
|
There's the normal fickle nature of markets, and then there's what...
|
|
PMN
|
I do not see the phrase "Best in Class" anywhere in the new...
|
|
PMN
|
Why would we want to remember Goldstein's "best in class"...
|
|
PMN
|
"The new CEO indicated: Yes, it would be a major cost reduction if we...
|
|
PMN
|
https://endpts.com/most-trusted-pharma-overtakes-tech-industry-for-top-spot...
|
|
PMN
|
Another article written by and for Biogen? Pablum. Dark matter in the...
|
|
PMN
|
Jan 9 (Reuters) - Private equity firms that deemed drug development too risky...
|
|
PMN
|
BB, the answer is "forward looking statements" In what...
|
|
PMN
|
I share your frustration bottombroker, and hope there is no institutional...
|
|
PMN
|
Given the clinical claims so far are mostly based on biomarkers I expected to...
|
|
PMN
|
Nice to see a quantitative measure, gives us a basis for speculation. And...
|
|
PMN
|
Maybe, but what if any CEO's message to the board is that we need a...
|
|
PMN
|
Bingo! What a pointless article, unless the point is that big pharma...
|
|
PMN
|
The Blarcamesine coverage comments are interesting, though our situation is...
|
|
PMN
|
Rotfl, you can't make this stuff up. "In documents, Biogen’s...
|
|
PMN
|
You know it really has to stink to get a report out of the House, so let'...
|
|
PMN
|
Whoopie, attending that healthcare conference, which they do every year. Oh...
|
|
PMN
|
Yes, exactly. So then the question for Promis management is whether there is...
|
|
PMN
|
I won't be entirely suprised if we get a massive share price increase...
|